• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
NEU 0.05% $20.51

NEUREN PHARMACEUTICALS LIMITED

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of trofinetide.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
NEU
Neuren Media and Analyst Coverage
14 15 16
21:55 937 457K
21:55 Last post  ashgood123 Comments Created with Sketch.  937  Views Created with Sketch.  457K 
NEU
Share Price
21:53 9.6K 4.2M
21:53 Last post  What A Gas Comments Created with Sketch.  9.6K  Views Created with Sketch.  4.2M 
NEU
Acadia
5 6 7
18:56 361 149K
TRENDING NEWS

BREAKING: RBA keeps interest rate on hold at 4.35% in line with expectations

NEWS
19 Mar 2024
18:56 Last post  Epichemist Comments Created with Sketch.  361  Views Created with Sketch.  149K 
NEU
Katelin’s Turn is HERE!!!
2 3 4
16/03/24 207 103K
16/03/24 Last post  mellan Comments Created with Sketch.  207  Views Created with Sketch.  103K 
NEU
NEU chart
24 25 26
15/03/24 1.5K 774K
15/03/24 Last post  vanni8282 Comments Created with Sketch.  1.5K  Views Created with Sketch.  774K 
NEU
Merck to acquire Prometheus in a US$ 10.8 b deal
2
14/03/24 107 61K
14/03/24 Last post  Piton72 Comments Created with Sketch.  107  Views Created with Sketch.  61K 
NEU
Upcoming Phase 2 Trial Announcement Dates
14/03/24 7 3.2K
14/03/24 Last post  Epichemist Comments Created with Sketch.  7  Views Created with Sketch.  3.2K 
NEU 12/03/24 0 742
12/03/24 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  742 

See All Discussions arrow Created with Sketch.

Timeline

Application for quotation of securities - NEU
12 Mar 14:24
 
2023 Results webinar
29 Feb 16:17
 
Neuren reports profit of $157 million for 2023
29 Feb 15:40
 
Appendix 4E and 2023 full year accounts
29 Feb 15:36
 
Neuren 2023 results investor webinar on 29 February 2024
29 Feb 09:27
 
DAYBUE net sales US$87.1 million in Q4 2023
28 Feb 09:54
 
View More arrow Created with Sketch.
(20min delay)
Last
$20.51
Change
0.010(0.05%)
Mkt cap ! $2.614B
Open High Low Value Volume
$20.44 $20.74 $20.32 $7.139M 348.4K

Buyers (Bids)

No. Vol. Price($)
1 555 $20.46
 

Sellers (Offers)

Price($) Vol. No.
$20.52 1221 2
View Market Depth
Last trade - 16.10pm 19/03/2024 (20 minute delay) ?
Last
$20.44
  Change
0.010 ( 0.30 %)
Open High Low Volume
$20.44 $20.74 $20.33 66578
Last updated 15.59pm 19/03/2024 ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.